London · Delayed Price · Currency is GBP · Price in USD Integrated Diagnostics Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 31% revenue growth and 78% net profit increase, driven by strong performance in Egypt, rapid expansion in Saudi Arabia, and improved margins in Nigeria. Management remains vigilant on regional risks and maintains flexibility on pricing and expansion plans.
Fiscal Year 2025
-
2025 saw 37% revenue growth, margin expansion, and strong performance in Egypt, Nigeria, and Saudi Arabia. 2026 guidance targets 25% sales growth, 200 new branches, and continued investment, with risks from regional geopolitics and currency volatility.
-
Strong nine-month 2025 results featured 41% revenue growth, margin expansion, and robust performance in Egypt, Jordan, Nigeria, and Saudi Arabia. Guidance for 2025 remains above 35% revenue growth and 30%+ EBITDA margin, with continued network expansion and cost discipline.
-
Strong H1 2025 results featured 42% revenue growth, margin expansion, and robust performance across Egypt, Saudi Arabia, Nigeria, and Jordan. Strategic investments, digitalization, and a resumed dividend underpin positive full-year guidance and continued market leadership.
-
Q1 2025 saw 35% revenue growth and margin expansion, driven by higher average revenue per test and effective cost control. Egypt, Jordan, and Nigeria delivered strong results, while Saudi Arabia ramp-up continues. Full-year revenue growth is guided at 30%+ with EBITDA margin above 30%.
Fiscal Year 2024
-
Record 2024 results with 39% revenue growth and margin improvements despite macro challenges. Expansion in Saudi and radiology, strong cash reserves, and a 33% revenue growth outlook for 2025, with dividend payout deferred to support growth and manage risks.
-
Revenue grew 34% year-on-year to EGP 4.1 billion, with strong margin improvements and net profit up 87%. Egypt led growth, while Nigeria and Saudi Arabia showed progress despite currency and regulatory challenges. Full-year guidance reaffirmed at 30% revenue growth and 30% EBITDA margin.
-
Revenue grew 33% year-over-year to EGP 2.5 billion, with strong margin expansion and net profit up 127%, driven by Egypt’s robust performance and cost controls. Guidance for 2024 targets 30% revenue growth and 30% EBITDA margin, with continued focus on operational efficiency and selective expansion.
-
Q1 2024 saw 28% revenue growth to EGP 1.2bn, with Egypt driving performance and margins improving across all levels. Guidance for 2024 is 30% revenue growth and a 30% EBITDA margin, excluding Saudi Arabia and non-recurring items.